MicroRNA-499a decelerates glioma cell proliferation while accelerating apoptosis through the suppression of Notch1 and the MAPK signaling pathway

• Published in: Brain research bulletin Vol. 142; pp. 96 - 106
• Main Authors: Wang, Bang-Qing, Yang, Bin, Yang, Hua-Chao, Wang, Jun-Yi, Hu, Sen, Gao, Yu-Shuai, Bu, Xing-Yao
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-09-2018
• Subjects: Adolescent; Adult; Aged; Apoptosis; Apoptosis - physiology; Brain - metabolism; Brain - pathology; Brain - surgery; Brain Neoplasms - metabolism; Brain Neoplasms - pathology; Brain Neoplasms - surgery; Cell Line, Tumor; Cell Proliferation - physiology; Child; Female; Gene Expression Regulation, Neoplastic; Glioma; Glioma - metabolism; Glioma - pathology; Glioma - surgery; Humans; Male; MAP Kinase Signaling System - physiology; MAPK signaling pathway; MicroRNA-449a; MicroRNAs - metabolism; Middle Aged; Notch1; Proliferation; Receptor, Notch1 - metabolism; Young Adult; Proliferation; Glioma; Notch1; MAPK signaling pathway; MicroRNA-449a; Apoptosis
• ISSN: 0361-9230; 1873-2747
• DOI: 10.1016/j.brainresbull.2018.06.005

•A study reported miR-499a targeting Notch1 in glioma cell proliferation & apoptosis.•miR-499a expresses highly and Notch1 expresses lowly in glioma cell.•miR-499a targets and inhibits Notch1.•miR-499a inhibits glioma cell proliferation by targeting Notch1via MAPK pathway.•Notch1 will be a new breakthrough in the diagnosis and treatment of glioma.
As the most common and lethal of intracranial tumors, glioma accounts for 81% of all malignant brain tumors. Research data have identified the role of microRNAs (miRs) as functional suppressors in the progression of Glioma. The present study aimed to, ascertain as to whether microRNA-499a (miR-499a) influences cell proliferation and apoptosis through the MAPK signaling pathway by targeting Notch1 in glioma. Both glioma and adjacent tissues between 2012–2016, were obtained from People’s Hospital of Zhengzhou University (Henan Provincial People’s Hospital). The collected glioma cells were treated with miR-449a mimic, miR-449a inhibitor, siRNA-Notch1, or SB230580 (an inhibitor of the MAPK signaling pathway). Verification of the targeting effect of miR-449a on Notch1 was provided by a dual-luciferase reporter gene assay. The expressions of miR-449a, Notch1, p38 mitogen-activated protein kinase (p38MAPK), extracellular regulated protein kinases (ERK1/2), B-cell lymphoma-2 (Bcl-2), Bcl-2 associated X protein (bax), CyclinD1, and phosphorylation of p38MAPK (p-p38MAPK) and ERK1/2 (p-ERK1/2) in tissues and cells were detected by means of reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analysis methods. Cellular processes of proliferation, cell cycle and apoptosis were evaluated by MTT and BrdU assays as well as flow cytometry, respectively. Notch1 was subsequently identified to be a target gene of miR-499a. After the cells were treated with miR-449a mimic, siRNA-Notch1 or SB230580, decreased expressions of Notch1, Bcl-2, CyclinD1, ERK1/2 and p-ERK1/2, cell proliferation as well as cells arrested at the S stage with elevated expressions levels of p38MAPK, p-p38MAPK, Bax, as well as increased cell apoptosis and number of cells arrested in G0/G1 stage were assessed. Taken together, based on the evidence obtained from the present study, assertions were subsequently made suggesting that MiR-499a targeted-inhibition of Notch1 may be a promising future therapeutic strategy for glioma treatment, by means of overexpressing of miR-499a resulting in the inhibition of glioma cell proliferation and promotion of cell apoptosis through suppression of the MAPK signaling pathway by decreasing Notch1.